Statistics from Altmetric.com
I read with great interest the recommendation for the management of rheumatoid arthritis (RA) by the European League Against Rheumatism (EULAR), especially the recommendation regarding glucocorticoid use: ‘Short-term glucocorticoids should be considered when initiating or changing conventional synthetic disease-modifying antirheumatic drugs (DMARDs), in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible’.1 This recommendation was primarily supported by randomised controlled studies that suggested the efficacy and acceptable safety of glucocorticoids in early RA compared with placebo.1 2 However, I …
Competing interests HO reports personal fees from Astellas, Ayumi, Daiichi, Sankyo, Eisai, Dainippon Sumitomo, Chugai Pharmaceutical, outside the submitted work. HO has received lecture fees from Mitsubishi Tanabe, Takeda, AbbVie, Chugai, BMS, Astellas, Ayumi, Daiichi-Sankyo, Eisai, Asahi Kasei and Dainippon Sumitomo.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.